MBOT
Microbot Medical Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$1.36
−4.23%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -28.0%
- EBIT
- -37.4%
- EPS
- +59.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +956.4%
- EBITDA
- -38.3%
- EPS
- -29.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -15.4%
- EBIT
- -26.8%
- Net income
- -14.8%
- EPS
- +60.3%
- Free cash flow
- -48.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026